Navigation Links
Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide
Date:11/9/2009

Once-daily INTUNIV is now available in US pharmacies in four dosage strengths (1 mg, 2 mg, 3 mg, and 4 mg) and is marketed in the United States by the existing Shire ADHD sales team of nearly 600 representatives. INTUNIV is not a controlled substance and has no known potential for abuse or dependence.

"INTUNIV is the newest ADHD treatment to receive FDA approval and the latest addition to the Shire ADHD portfolio. The availability of INTUNIV now allows physicians to prescribe the first and only nonscheduled alpha-2A receptor agonist indicated for the treatment of ADHD to help their patients manage a range of ADHD symptoms," said Michael Yasick, Senior Vice President of the ADHD Business Unit at Shire. "Shire is proud to provide physicians and the ADHD community with a novel treatment choice, which expands the range of available treatment options, allowing physicians to optimize the management of ADHD."

The commitment of Shire to making INTUNIV available for ADHD patients is consistent with the company's strategy to expand and diversify its ADHD portfolio, which now consists of four ADHD treatment options of scheduled and nonscheduled medicines in the United States and three medicines approved for the treatment of ADHD outside the United States.

About INTUNIV

The efficacy of INTUNIV in the treatment of ADHD was established in two, similarly designed, placebo-controlled clinical trials in children and adolescents aged 6 to 17 years who met Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV®) criteria for ADHD. Statistically significant improvements were reported by investigators, parents, and teachers.

The first pivotal trial was a phase III, double-blind, parallel-group trial, in which investigators randomized 345 children aged 6 to 17 years to either
'/>"/>

SOURCE Shire plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C
2. New Data Show Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Demonstrated Significant ADHD Symptom Reduction when Assessed Using the Oppositional Subscale of the Conners ADHD Rating Scale
3. Transave Announces Positive Phase II Results For Once-Daily ARIKACE(TM) in the Treatment of Non-CF Bronchiectasis Patients Who Have Pseudomonas Lung Infections
4. Shire Announces FDA Approval of Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17
5. ISTA Pharmaceuticals Announces Positive Preliminary Phase 3 Clinical Results to Support sNDA Filing for Once-Daily Xibrom(TM) 0.09%
6. Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing
7. New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting
8. New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation
9. ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09%
10. Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
11. Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 31, 2015 Magnaquest, a ... data and cloud computing operators has signed a ... giant for Internet of Things (IoT) related initiative. ... on subscription model.      (Logo: ... striving for business innovations to make healthcare services ...
(Date:7/30/2015)... VIEW, Calif. , July 30, 2015 ... it will release its second quarter 2015 financial results ... 2015.   In conjunction with the release, the Company ... at 5:00 p.m. Eastern Time on ... of the quarter and other business developments. ...
(Date:7/30/2015)... edition of #MedicareMonday on Medicare,s 50 th anniversary. As Medicare celebrates 50 years, ... the success of the prescription drug benefit, commonly referred to as Part D. ... videos here: http://onphr.ma/1INp9qQ ... ... More ...
Breaking Medicine Technology:Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3
... in Combination with Chemotherapy, FREMONT, Calif. ... pharmaceutical company discovering and developing novel,RNA interference ... Research published results on efficacy of siRNA ... lung cancer (NSCLC) in,the edition dated October ...
... Pivotal Data Show Prophylaxis Treatment with Kogenate FS ... in Children with No Pre-Existing,Joint Damage, BERKELEY, ... that the U.S. Food and Drug Administration (FDA) ... to reduce the frequency of bleeding episodes and ...
Cached Medicine Technology:Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 2Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 3Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 4FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 2FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 3FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 4FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 5
(Date:7/31/2015)... ... July 31, 2015 , ... Eldermark ... for LeadingAge’s Center for Aging Services Technologies (CAST) Medication Management Technologies whitepaper. The ... post-acute care providers understand the benefits of using medication management technologies . ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... Hospital's Karmanos Center for Natural Birth . The Karmanos Center for ... safe natural childbirth experience. With nurses and caregivers that are trained in holistic ...
(Date:7/31/2015)... ... July 31, 2015 , ... New Energy Works Timberframers ... Amphitheater in McMinnville, Oregon August 15th, 2015 from 9am – 12pm. Timber frame ... important day for the entire community as the culmination of months of effort, planning, ...
(Date:7/31/2015)... ... July 31, 2015 , ... An article entitled ... talked about a woman’s unfortunate experience having cosmetic skin procedures done by a ... resulted in blistering, swelling, bruising, and pain. This woman’s experience is only one ...
(Date:7/31/2015)... ... July 31, 2015 , ... In the most recent testosterone ... in the Northern District of Illinois, Androgel testosterone attorneys report that a “Mini Status ... entry was made recording the minutes of the status conference, which was held that ...
Breaking Medicine News(10 mins):Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 3Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 2Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 3Health News:Dermatologists Discuss Rise in Unqualified Practitioners of Cosmetic Dermatology 2Health News:Dermatologists Discuss Rise in Unqualified Practitioners of Cosmetic Dermatology 3Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 2Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 3Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 4
... Joins Thousands of Participants in Inspirational Closing Ceremony; ... Breast Cancer Organizations, WASHINGTON, May 4 ... Reese Witherspoon was a special guest at the,sixth ... this weekend,cheering on and joining walkers on their ...
... to an expanding waist line, weight gain and a tendency ... of a study published today in the journal Nature Genetics. ... is significantly more common in those with Indian Asian than ... Heart Foundation, could lead to better ways of treating obesity. ...
... knowledge gap, experts say , , SUNDAY, May 4 (HealthDay ... surprisingly low knowledge of child development, including basic concepts ... should act, a new study finds. , For instance, ... 1-year-olds can,t tell the difference between right and wrong, ...
... Study shows only 49% intended to do so if child ... News) -- New research shows that only half of American ... papillomavirus (HPV) if the girls are under the age of ... which is sexually transmitted, is the primary cause of cervical ...
... assumptions, children are more vulnerable to the harmful effects ... they are in early childhood, according to a Cincinnati ... 4 at the annual meeting of the Pediatric Academic ... protecting toddlers from lead exposure, our study shows that ...
... U.S. parents have a surprisingly low-level knowledge of ... childs physical, social and emotional growth, according research ... which suggest that such false parenting assumptions can ... kids of much-needed cognitive stimulation, will be presented ...
Cached Medicine News:Health News:Reese Witherspoon Helps Celebrate Avon Walk for Breast Cancer Washington, D.C. - Weekend-Long Event Raises $8.1 Million 2Health News:Reese Witherspoon Helps Celebrate Avon Walk for Breast Cancer Washington, D.C. - Weekend-Long Event Raises $8.1 Million 3Health News:Reese Witherspoon Helps Celebrate Avon Walk for Breast Cancer Washington, D.C. - Weekend-Long Event Raises $8.1 Million 4Health News:Reese Witherspoon Helps Celebrate Avon Walk for Breast Cancer Washington, D.C. - Weekend-Long Event Raises $8.1 Million 5Health News:Reese Witherspoon Helps Celebrate Avon Walk for Breast Cancer Washington, D.C. - Weekend-Long Event Raises $8.1 Million 6Health News:Gene sequence that can make half of us fatter is discovered 2Health News:One-Third of Parents Lack Facts About Child Development 2Health News:One-Third of Parents Lack Facts About Child Development 3Health News:Many Moms Unwilling to Have Younger Daughters Get HPV Vaccine 2Health News:Many Moms Unwilling to Have Younger Daughters Get HPV Vaccine 3Health News:Children more vulnerable to harmful effects of lead 2Health News:Nearly one-third of US parents don't know what to expect of infants 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: